FDX2 genetic mutations have been associated to the development of a rare mitochondrial disease, named episodic mitochondrial myopathy with or without optic atrophy and reversible leukoencephalopathy (MEOAL, OMIM number: 251900) (Aggarwal et al. 2022; Gkiourtzis et al. 2023; Gurgel‐Giannetti et al. 2018; Lebigot et al. 2017; Montealegre et al. 2022; Spiegel et al. 2014; Wongkittichote et al. 2024). Here, FDX2 is linked to hereditary optic atrophy.